<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00885118</url>
  </required_header>
  <id_info>
    <org_study_id>1245.15</org_study_id>
    <nct_id>NCT00885118</nct_id>
  </id_info>
  <brief_title>4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)</brief_title>
  <official_title>A Phase II, Randomised, Double-blind, Placebo-controlled, Multiple Dose Study to Evaluate Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Once Daily Oral Administration of BI 10773 (1 mg, 5 mg, 10 mg, and 25 mg) for 28 Days in Japanese Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of this trial is to evaluate the pharmacodynamics, pharmacokinetics, safety,
      and tolerability of once daily oral administration of BI 10773 administered for 28 days in
      Japanese patients with T2DM.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Urine Glucose Excretion</measure>
    <time_frame>baseline and 28 days</time_frame>
    <description>Change from baseline in Urine glucose excretion to 28 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose</measure>
    <time_frame>baseline and 28 days</time_frame>
    <description>Change from baseline in Fasting plasma glucose to 28 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in 8-point Glucose</measure>
    <time_frame>baseline and 27 days</time_frame>
    <description>Change from baseline in 8-point glucose to 27 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HbA1c</measure>
    <time_frame>baseline and 28 days</time_frame>
    <description>Change from baseline in HbA1c to 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fructosamine</measure>
    <time_frame>baseline and 28 days</time_frame>
    <description>Change from baseline in Fructosamine to 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 1,5-anhydroglucitol</measure>
    <time_frame>baseline and 28 days</time_frame>
    <description>Change from baseline in 1,5-anhydroglucitol to 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Insulin</measure>
    <time_frame>baseline and 28 days</time_frame>
    <description>Change from baseline in Fasting insulin to 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Area Under the Curve of Plasma Glucose Levels Until 4 Hours After Intake of a Standardised Food (Meal Tolerance Test)</measure>
    <time_frame>baseline and 28 days</time_frame>
    <description>Change from baseline in the area under the curve of plasma glucose levels until 4 hours after intake of a standardised food (meal tolerance test) to 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Area Under the Curve of Glucagon Levels Until 4 Hours After Intake of a Standardised Food (Meal Tolerance Test)</measure>
    <time_frame>baseline and 28 days</time_frame>
    <description>Change from baseline in the area under the curve of glucagon levels until 4 hours after intake of a standardised food (meal tolerance test) to 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Area Under the Curve of Insulin Levels Until 4 Hours After Intake of a Standardised Food (Meal Tolerance Test)</measure>
    <time_frame>baseline and 28 days</time_frame>
    <description>Change from baseline in the area under the curve of insulin levels until 4 hours after intake of a standardised food (meal tolerance test) to 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCτ,1</measure>
    <time_frame>Predose and 15 minutes (min), 30min, 45min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 23h55min after first drug administration</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma after administration of the first dose over a uniform dosing interval τ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz</measure>
    <time_frame>Predose and 15 minutes (min), 30min, 45min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 23h55min after first drug administration</time_frame>
    <description>area under the concentration-time curve of the analyte in plasma over the time interval from 0 to last quantifiable plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>Predose and 15 minutes (min), 30min, 45min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 23h55min after first drug administration</time_frame>
    <description>area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Predose and 15 minutes (min), 30min, 45min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 23h55min after first drug administration</time_frame>
    <description>maximum measured concentration of the analyte in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Predose and 15 minutes (min), 30min, 45min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 23h55min after first drug administration</time_frame>
    <description>terminal half-life of the analyte in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>Predose and 15 minutes (min), 30min, 45min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 23h55min after first drug administration</time_frame>
    <description>apparent clearance of the analyte in plasma after extravascular administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F</measure>
    <time_frame>Predose and 15 minutes (min), 30min, 45min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 23h55min after first drug administration</time_frame>
    <description>apparent volume of distribution during the terminal phase λz following an extravascular dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae0-24</measure>
    <time_frame>0-5, 5-12, 12-24 hour after first drug administration</time_frame>
    <description>amount of the analyte that is eliminated in urine over the time interval 0 to 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fe0-24</measure>
    <time_frame>0-5, 5-12, 12-24 hour after first drug administration</time_frame>
    <description>fraction of the analyte excreted unchanged in urine from time interval 0 to 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLR,0-24</measure>
    <time_frame>Predose and 15 minutes (min), 30min, 45min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 23h55min, 0-5h, 5-12h, 12-24h after first drug administration</time_frame>
    <description>renal clearance of the analyte in plasma after extravascular administration - based on 0-24 hours data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCτ,ss</measure>
    <time_frame>Predose and 15 minutes (min), 30min, 45min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h after last drug administration</time_frame>
    <description>area under the concentration-time curve of the analyte in plasma over a uniform dosing interval τ at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss</measure>
    <time_frame>Predose and 15 minutes (min), 30min, 45min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h 48h, 72h after last drug administration</time_frame>
    <description>maximum measured concentration of the analyte in plasma at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2,ss</measure>
    <time_frame>Predose and 15 minutes (min), 30min, 45min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h 48h, 72h after last drug administration</time_frame>
    <description>terminal half-life of the analyte in plasma at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F,ss</measure>
    <time_frame>Predose and 15 minutes (min), 30min, 45min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h 48h, 72h after last drug administration</time_frame>
    <description>apparent clearance of the analyte in plasma after extravascular administration at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F,ss</measure>
    <time_frame>Predose and 15 minutes (min), 30min, 45min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h 48h, 72h after last drug administration</time_frame>
    <description>apparent volume of distribution during the terminal phase λz following an extravascular dose at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RA,Cmax</measure>
    <time_frame>Predose, 15min, 30min, 45min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 23h55min after first drug administration, and predose, 15min, 30min, 45min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h after last drug administration</time_frame>
    <description>accumulation ratios of the analyte in plasma after 28 doses (once daily) over a uniform dosing interval τ, based on Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RA,AUC</measure>
    <time_frame>Predose, 15min, 30min, 45min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 23h55min after first drug administration, and predose, 15min, 30min, 45min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h after last drug administration</time_frame>
    <description>accumulation ratios of the analyte in plasma after 28 doses (once daily) over a uniform dosing interval τ, based on AUCτ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae0-24,ss</measure>
    <time_frame>0-5, 5-12, 12-24 hour after last drug administration</time_frame>
    <description>amount of the analyte that is eliminated in urine at steady state over the time interval 0 to 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fe0-24,ss</measure>
    <time_frame>0-5, 5-12, 12-24 hour after last drug administration</time_frame>
    <description>fraction of the analyte excreted unchanged in urine at steady state from time interval 0 to 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLR,ss</measure>
    <time_frame>Predose and 15 minutes (min), 30min, 45min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 0-5h, 5-12h, 12-24h after last drug administration</time_frame>
    <description>renal clearance of the analyte at steady state determined over the dosing interval τ</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>BI 10773 low dose quaque die (QD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive a BI 10773 low dose tablet and a placebo tablet once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 mid-low dose QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive a BI 10773 middle dose tablet and a placebo tablet once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 mid-high dose QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive two tablets of BI 10773 middle dose once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 high dose QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive a BI 10773 high dose tablet and a placebo tablet once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patient to receive two tablets of placebo once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (middle dose)</intervention_name>
    <description>Placebo tablets once a day</description>
    <arm_group_label>BI 10773 mid-low dose QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets once a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>BI 10773 middle dose tablets once a day</description>
    <arm_group_label>BI 10773 mid-high dose QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>BI 10773 high dose tablets once a day</description>
    <arm_group_label>BI 10773 high dose QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>BI 10773 middle dose tablets once a day</description>
    <arm_group_label>BI 10773 mid-low dose QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (high dose)</intervention_name>
    <description>Placebo tablets once a day</description>
    <arm_group_label>BI 10773 high dose QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>BI 10773 low dose tablets once a day</description>
    <arm_group_label>BI 10773 low dose quaque die (QD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (low dose)</intervention_name>
    <description>Placebo tablets once a day</description>
    <arm_group_label>BI 10773 low dose quaque die (QD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Japanese male or female patients with T2DM treated with diet and exercise alone or
             with one hypoglycaemic drug other than glitazones.

          2. Hemoglobin A1c (HbA1c) at screening (Visit 1)

               -  For patients treated with 1 other oral antidiabetic drug: HbA1c between 6.5% and
                  9.0%.

               -  For patients not treated with any antidiabetic drug: HbA1c between 7.0% and
                  10.0%.

          3. Age between 20 and 70 years

          4. Body mass index (BMI) between18.0 and 40.0 kg/m2

          5. Signed and dated written informed consent before admission to the trial in accordance
             with the Good Clinical Practice (GCP) and the local legislation.

        Exclusion criteria:

          1. Antidiabetic treatment with insulin or glitazones within 3 months before obtaining
             informed consent or with more than 1 oral hypoglycaemic agent at the time of informed
             consent

          2. Fasted blood glucose of &gt;240 mg/dL (&gt;13.3 mmol/L) or a randomly determined blood
             glucose level of &gt;400 mg/dL (22.2 mmol/L) on 2 consecutive days during wash-out
             period.

          3. Myocardial infarction, stroke, or transient ischaemic attack within 6 months before
             informed consent.

          4. Clinically relevant concomitant diseases other than T2DM, hyperlipidaemia, and
             medically treated hypertension before the first administration such as

               -  Renal insufficiency (calculated estimated glomerular filtration rate &lt;60)

               -  Cardiac insufficiency of New York Heart Association (NYHA) II-IV or other known
                  cardiovascular diseases including hypertension of &gt;160/95 mmHg,

               -  Neurological disorders (such as epilepsy) or psychiatric disorders

               -  Acute or clinically relevant chronic infections (e.g., human immunodeficiency
                  virus, hepatitis, repeated urogenital infections)

               -  Any gastrointestinal, hepatic, respiratory, endocrine, or immunological disorder

          5. Patients under treatment with any concomitant medication except for the following
             drugs at the time of informed consent.:

               -  Statins.

               -  Antihypertensives (diuretics not allowed)

               -  alpha-Blockers for benign prostate hypertrophy

               -  Occasional use of acetylsalicylic acid, ibuprofen, or paracetamol

          6. Additional inclusion/exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1245.15.003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hachioji, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.15.002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koganei, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.15.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nakano-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.15.005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suita, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.15.004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yokohama, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2009</study_first_submitted>
  <study_first_submitted_qc>April 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2009</study_first_posted>
  <results_first_submitted>May 16, 2014</results_first_submitted>
  <results_first_submitted_qc>May 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 16, 2014</results_first_posted>
  <last_update_submitted>November 13, 2014</last_update_submitted>
  <last_update_submitted_qc>November 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Treatment with placebo once daily</description>
        </group>
        <group group_id="P2">
          <title>Empa 1 mg</title>
          <description>Treatment with Empa 1 mg once daily</description>
        </group>
        <group group_id="P3">
          <title>Empa 5 mg</title>
          <description>Treatment with Empa 5 mg once daily</description>
        </group>
        <group group_id="P4">
          <title>Empa 10 mg</title>
          <description>Treatment with Empa 10 mg once daily</description>
        </group>
        <group group_id="P5">
          <title>Empa 25 mg</title>
          <description>Treatment with Empa 25 mg once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not defined above</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Treatment with placebo once daily</description>
        </group>
        <group group_id="B2">
          <title>Empa 1 mg</title>
          <description>Treatment with Empa 1 mg once daily</description>
        </group>
        <group group_id="B3">
          <title>Empa 5 mg</title>
          <description>Treatment with Empa 5 mg once daily</description>
        </group>
        <group group_id="B4">
          <title>Empa 10 mg</title>
          <description>Treatment with Empa 10 mg once daily</description>
        </group>
        <group group_id="B5">
          <title>Empa 25 mg</title>
          <description>Treatment with Empa 25 mg once daily</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="20"/>
            <count group_id="B5" value="19"/>
            <count group_id="B6" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.2" spread="10.0"/>
                    <measurement group_id="B2" value="58.6" spread="8.2"/>
                    <measurement group_id="B3" value="53.9" spread="9.9"/>
                    <measurement group_id="B4" value="55.8" spread="8.0"/>
                    <measurement group_id="B5" value="60.8" spread="8.7"/>
                    <measurement group_id="B6" value="57.2" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Urine Glucose Excretion</title>
        <description>Change from baseline in Urine glucose excretion to 28 days</description>
        <time_frame>baseline and 28 days</time_frame>
        <population>Full analysis set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Treatment with placebo once daily</description>
          </group>
          <group group_id="O2">
            <title>Empa 1 mg</title>
            <description>Treatment with Empa 1 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Empa 5 mg</title>
            <description>Treatment with Empa 5 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Empa 10 mg</title>
            <description>Treatment with Empa 10 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Empa 25 mg</title>
            <description>Treatment with Empa 25 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urine Glucose Excretion</title>
          <description>Change from baseline in Urine glucose excretion to 28 days</description>
          <population>Full analysis set (FAS)</population>
          <units>mg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="599.763" spread="4497.460"/>
                    <measurement group_id="O2" value="43428.245" spread="4598.593"/>
                    <measurement group_id="O3" value="81564.440" spread="4460.086"/>
                    <measurement group_id="O4" value="89189.527" spread="4704.967"/>
                    <measurement group_id="O5" value="86220.111" spread="4828.541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 1mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>42828.482</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6487.174</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>29936.586</ci_lower_limit>
            <ci_upper_limit>55720.378</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 5mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>80964.677</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6303.820</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>68437.160</ci_lower_limit>
            <ci_upper_limit>93492.194</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 10mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>88589.764</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6544.604</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>75583.738</ci_lower_limit>
            <ci_upper_limit>101595.790</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 25mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>85620.348</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6610.091</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>72484.181</ci_lower_limit>
            <ci_upper_limit>98756.515</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Fasting Plasma Glucose</title>
        <description>Change from baseline in Fasting plasma glucose to 28 days</description>
        <time_frame>baseline and 28 days</time_frame>
        <population>Full analysis set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Treatment with placebo once daily</description>
          </group>
          <group group_id="O2">
            <title>Empa 1 mg</title>
            <description>Treatment with Empa 1 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Empa 5 mg</title>
            <description>Treatment with Empa 5 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Empa 10 mg</title>
            <description>Treatment with Empa 10 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Empa 25 mg</title>
            <description>Treatment with Empa 25 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose</title>
          <description>Change from baseline in Fasting plasma glucose to 28 days</description>
          <population>Full analysis set (FAS)</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.436" spread="2.860"/>
                    <measurement group_id="O2" value="-28.116" spread="2.965"/>
                    <measurement group_id="O3" value="-35.355" spread="2.865"/>
                    <measurement group_id="O4" value="-41.643" spread="3.009"/>
                    <measurement group_id="O5" value="-42.670" spread="3.089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 1mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0030</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-12.680</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.155</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.936</ci_lower_limit>
            <ci_upper_limit>-4.424</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 5mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-19.920</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.919</ci_lower_limit>
            <ci_upper_limit>-11.921</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 10mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-26.208</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.168</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.490</ci_lower_limit>
            <ci_upper_limit>-17.925</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 25mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-27.235</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.202</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.586</ci_lower_limit>
            <ci_upper_limit>-18.884</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in 8-point Glucose</title>
        <description>Change from baseline in 8-point glucose to 27 days</description>
        <time_frame>baseline and 27 days</time_frame>
        <population>Full analysis set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Treatment with placebo once daily</description>
          </group>
          <group group_id="O2">
            <title>Empa 1 mg</title>
            <description>Treatment with Empa 1 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Empa 5 mg</title>
            <description>Treatment with Empa 5 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Empa 10 mg</title>
            <description>Treatment with Empa 10 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Empa 25 mg</title>
            <description>Treatment with Empa 25 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 8-point Glucose</title>
          <description>Change from baseline in 8-point glucose to 27 days</description>
          <population>Full analysis set (FAS)</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.381" spread="3.932"/>
                    <measurement group_id="O2" value="-35.263" spread="4.121"/>
                    <measurement group_id="O3" value="-39.867" spread="3.903"/>
                    <measurement group_id="O4" value="-43.646" spread="4.113"/>
                    <measurement group_id="O5" value="-45.721" spread="4.187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 1mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0030</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-17.883</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.861</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.529</ci_lower_limit>
            <ci_upper_limit>-6.236</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 5mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-22.487</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.445</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.308</ci_lower_limit>
            <ci_upper_limit>-11.665</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 10mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-26.265</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.785</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.762</ci_lower_limit>
            <ci_upper_limit>-14.768</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 25mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-28.340</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.699</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.665</ci_lower_limit>
            <ci_upper_limit>-17.015</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HbA1c</title>
        <description>Change from baseline in HbA1c to 28 days</description>
        <time_frame>baseline and 28 days</time_frame>
        <population>Full analysis set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Treatment with placebo once daily</description>
          </group>
          <group group_id="O2">
            <title>Empa 1 mg</title>
            <description>Treatment with Empa 1 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Empa 5 mg</title>
            <description>Treatment with Empa 5 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Empa 10 mg</title>
            <description>Treatment with Empa 10 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Empa 25 mg</title>
            <description>Treatment with Empa 25 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c</title>
          <description>Change from baseline in HbA1c to 28 days</description>
          <population>Full analysis set (FAS)</population>
          <units>percentage of HbA1c</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.420" spread="0.089"/>
                    <measurement group_id="O2" value="-0.659" spread="0.093"/>
                    <measurement group_id="O3" value="-0.717" spread="0.090"/>
                    <measurement group_id="O4" value="-0.849" spread="0.094"/>
                    <measurement group_id="O5" value="-0.815" spread="0.096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 1mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0705</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.239</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.130</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.498</ci_lower_limit>
            <ci_upper_limit>-0.020</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 5mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0203</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.296</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.125</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.545</ci_lower_limit>
            <ci_upper_limit>-0.047</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 10mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0014</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.429</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.130</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.687</ci_lower_limit>
            <ci_upper_limit>-0.170</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 25mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0033</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.395</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.131</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.654</ci_lower_limit>
            <ci_upper_limit>-0.135</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fructosamine</title>
        <description>Change from baseline in Fructosamine to 28 days</description>
        <time_frame>baseline and 28 days</time_frame>
        <population>Full analysis set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Treatment with placebo once daily</description>
          </group>
          <group group_id="O2">
            <title>Empa 1 mg</title>
            <description>Treatment with Empa 1 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Empa 5 mg</title>
            <description>Treatment with Empa 5 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Empa 10 mg</title>
            <description>Treatment with Empa 10 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Empa 25 mg</title>
            <description>Treatment with Empa 25 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fructosamine</title>
          <description>Change from baseline in Fructosamine to 28 days</description>
          <population>Full analysis set (FAS)</population>
          <units>umol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.436" spread="12.289"/>
                    <measurement group_id="O2" value="4.091" spread="12.663"/>
                    <measurement group_id="O3" value="-2.453" spread="12.362"/>
                    <measurement group_id="O4" value="-26.294" spread="12.933"/>
                    <measurement group_id="O5" value="-28.275" spread="13.282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 1mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4823</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>12.527</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>17.755</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.757</ci_lower_limit>
            <ci_upper_limit>47.811</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 5mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7305</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.984</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>17.313</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.422</ci_lower_limit>
            <ci_upper_limit>40.390</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 10mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3213</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-17.858</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>17.903</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-53.438</ci_lower_limit>
            <ci_upper_limit>17.721</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 25mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2768</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-19.838</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>18.130</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-55.869</ci_lower_limit>
            <ci_upper_limit>16.192</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 1,5-anhydroglucitol</title>
        <description>Change from baseline in 1,5-anhydroglucitol to 28 days</description>
        <time_frame>baseline and 28 days</time_frame>
        <population>Full analysis set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Treatment with placebo once daily</description>
          </group>
          <group group_id="O2">
            <title>Empa 1 mg</title>
            <description>Treatment with Empa 1 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Empa 5 mg</title>
            <description>Treatment with Empa 5 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Empa 10 mg</title>
            <description>Treatment with Empa 10 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Empa 25 mg</title>
            <description>Treatment with Empa 25 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 1,5-anhydroglucitol</title>
          <description>Change from baseline in 1,5-anhydroglucitol to 28 days</description>
          <population>Full analysis set (FAS)</population>
          <units>ug/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.174" spread="0.439"/>
                    <measurement group_id="O2" value="-3.018" spread="0.581"/>
                    <measurement group_id="O3" value="-3.435" spread="0.615"/>
                    <measurement group_id="O4" value="-2.863" spread="0.622"/>
                    <measurement group_id="O5" value="-3.713" spread="0.982"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 1mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.192</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.728</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.653</ci_lower_limit>
            <ci_upper_limit>-2.731</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 5mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.609</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.756</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.126</ci_lower_limit>
            <ci_upper_limit>-3.091</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 10mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.036</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.762</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.565</ci_lower_limit>
            <ci_upper_limit>-2.508</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 25mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.887</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.076</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.048</ci_lower_limit>
            <ci_upper_limit>-2.726</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Insulin</title>
        <description>Change from baseline in Fasting insulin to 28 days</description>
        <time_frame>baseline and 28 days</time_frame>
        <population>Full analysis set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Treatment with placebo once daily</description>
          </group>
          <group group_id="O2">
            <title>Empa 1 mg</title>
            <description>Treatment with Empa 1 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Empa 5 mg</title>
            <description>Treatment with Empa 5 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Empa 10 mg</title>
            <description>Treatment with Empa 10 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Empa 25 mg</title>
            <description>Treatment with Empa 25 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Insulin</title>
          <description>Change from baseline in Fasting insulin to 28 days</description>
          <population>Full analysis set (FAS)</population>
          <units>uU/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.387" spread="0.287"/>
                    <measurement group_id="O2" value="-0.866" spread="0.295"/>
                    <measurement group_id="O3" value="-0.766" spread="0.287"/>
                    <measurement group_id="O4" value="-1.730" spread="0.301"/>
                    <measurement group_id="O5" value="-1.643" spread="0.312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 1mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2498</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.480</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.414</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.302</ci_lower_limit>
            <ci_upper_limit>0.343</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 5mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3544</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.379</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.408</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.189</ci_lower_limit>
            <ci_upper_limit>0.430</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 10mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0018</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.343</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.416</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.171</ci_lower_limit>
            <ci_upper_limit>-0.516</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 25mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0037</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.257</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.421</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.094</ci_lower_limit>
            <ci_upper_limit>-0.419</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Area Under the Curve of Plasma Glucose Levels Until 4 Hours After Intake of a Standardised Food (Meal Tolerance Test)</title>
        <description>Change from baseline in the area under the curve of plasma glucose levels until 4 hours after intake of a standardised food (meal tolerance test) to 28 days</description>
        <time_frame>baseline and 28 days</time_frame>
        <population>Full analysis set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Treatment with placebo once daily</description>
          </group>
          <group group_id="O2">
            <title>Empa 1 mg</title>
            <description>Treatment with Empa 1 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Empa 5 mg</title>
            <description>Treatment with Empa 5 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Empa 10 mg</title>
            <description>Treatment with Empa 10 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Empa 25 mg</title>
            <description>Treatment with Empa 25 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Area Under the Curve of Plasma Glucose Levels Until 4 Hours After Intake of a Standardised Food (Meal Tolerance Test)</title>
          <description>Change from baseline in the area under the curve of plasma glucose levels until 4 hours after intake of a standardised food (meal tolerance test) to 28 days</description>
          <population>Full analysis set (FAS)</population>
          <units>hr*mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-81.357" spread="10.481"/>
                    <measurement group_id="O2" value="-176.771" spread="10.924"/>
                    <measurement group_id="O3" value="-190.837" spread="10.554"/>
                    <measurement group_id="O4" value="-212.693" spread="11.023"/>
                    <measurement group_id="O5" value="-217.698" spread="11.247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 1mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-95.414</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>15.388</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-125.995</ci_lower_limit>
            <ci_upper_limit>-64.833</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 5mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-109.480</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>14.670</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-138.633</ci_lower_limit>
            <ci_upper_limit>-80.327</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 10mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-131.336</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>15.354</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-161.848</ci_lower_limit>
            <ci_upper_limit>-100.824</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 25mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-136.341</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>15.357</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-166.860</ci_lower_limit>
            <ci_upper_limit>-105.823</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Area Under the Curve of Glucagon Levels Until 4 Hours After Intake of a Standardised Food (Meal Tolerance Test)</title>
        <description>Change from baseline in the area under the curve of glucagon levels until 4 hours after intake of a standardised food (meal tolerance test) to 28 days</description>
        <time_frame>baseline and 28 days</time_frame>
        <population>Full analysis set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Treatment with placebo once daily</description>
          </group>
          <group group_id="O2">
            <title>Empa 1 mg</title>
            <description>Treatment with Empa 1 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Empa 5 mg</title>
            <description>Treatment with Empa 5 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Empa 10 mg</title>
            <description>Treatment with Empa 10 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Empa 25 mg</title>
            <description>Treatment with Empa 25 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Area Under the Curve of Glucagon Levels Until 4 Hours After Intake of a Standardised Food (Meal Tolerance Test)</title>
          <description>Change from baseline in the area under the curve of glucagon levels until 4 hours after intake of a standardised food (meal tolerance test) to 28 days</description>
          <population>Full analysis set (FAS)</population>
          <units>hr*pg/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.452" spread="9.177"/>
                    <measurement group_id="O2" value="-0.785" spread="9.383"/>
                    <measurement group_id="O3" value="7.124" spread="9.138"/>
                    <measurement group_id="O4" value="-17.478" spread="9.635"/>
                    <measurement group_id="O5" value="-12.437" spread="9.964"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 1mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0883</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>22.668</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>13.152</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.470</ci_lower_limit>
            <ci_upper_limit>48.805</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 5mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0203</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>30.576</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>12.941</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.859</ci_lower_limit>
            <ci_upper_limit>56.293</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 10mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6541</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.974</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>13.289</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.434</ci_lower_limit>
            <ci_upper_limit>32.382</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 25mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4206</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>11.015</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>13.612</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.036</ci_lower_limit>
            <ci_upper_limit>38.066</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Area Under the Curve of Insulin Levels Until 4 Hours After Intake of a Standardised Food (Meal Tolerance Test)</title>
        <description>Change from baseline in the area under the curve of insulin levels until 4 hours after intake of a standardised food (meal tolerance test) to 28 days</description>
        <time_frame>baseline and 28 days</time_frame>
        <population>Full analysis set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Treatment with placebo once daily</description>
          </group>
          <group group_id="O2">
            <title>Empa 1 mg</title>
            <description>Treatment with Empa 1 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Empa 5 mg</title>
            <description>Treatment with Empa 5 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Empa 10 mg</title>
            <description>Treatment with Empa 10 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Empa 25 mg</title>
            <description>Treatment with Empa 25 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Area Under the Curve of Insulin Levels Until 4 Hours After Intake of a Standardised Food (Meal Tolerance Test)</title>
          <description>Change from baseline in the area under the curve of insulin levels until 4 hours after intake of a standardised food (meal tolerance test) to 28 days</description>
          <population>Full analysis set (FAS)</population>
          <units>hr*uU/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.948" spread="2.819"/>
                    <measurement group_id="O2" value="-5.921" spread="2.896"/>
                    <measurement group_id="O3" value="-11.396" spread="2.811"/>
                    <measurement group_id="O4" value="-12.695" spread="2.982"/>
                    <measurement group_id="O5" value="-7.170" spread="3.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 1mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0318</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.869</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.066</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.949</ci_lower_limit>
            <ci_upper_limit>-0.789</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 5mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-14.344</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.966</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.225</ci_lower_limit>
            <ci_upper_limit>-6.462</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 10mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-15.642</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.131</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.853</ci_lower_limit>
            <ci_upper_limit>-7.432</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Difference calculated as empa 25mg minus placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0164</p_value>
            <method>ANCOVA</method>
            <method_desc>The baseline value was included as a continuous covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-10.118</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.137</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.339</ci_lower_limit>
            <ci_upper_limit>-1.897</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUCτ,1</title>
        <description>Area under the concentration-time curve of the analyte in plasma after administration of the first dose over a uniform dosing interval τ</description>
        <time_frame>Predose and 15 minutes (min), 30min, 45min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 23h55min after first drug administration</time_frame>
        <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 1 mg</title>
            <description>Treatment with Empa 1 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Empa 5 mg</title>
            <description>Treatment with Empa 5 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Empa 10 mg</title>
            <description>Treatment with Empa 10 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Empa 25 mg</title>
            <description>Treatment with Empa 25 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>AUCτ,1</title>
          <description>Area under the concentration-time curve of the analyte in plasma after administration of the first dose over a uniform dosing interval τ</description>
          <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216" spread="18.4"/>
                    <measurement group_id="O2" value="938" spread="44.2"/>
                    <measurement group_id="O3" value="2040" spread="19.4"/>
                    <measurement group_id="O4" value="5190" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-tz</title>
        <description>area under the concentration-time curve of the analyte in plasma over the time interval from 0 to last quantifiable plasma concentration</description>
        <time_frame>Predose and 15 minutes (min), 30min, 45min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 23h55min after first drug administration</time_frame>
        <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 1 mg</title>
            <description>Treatment with Empa 1 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Empa 5 mg</title>
            <description>Treatment with Empa 5 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Empa 10 mg</title>
            <description>Treatment with Empa 10 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Empa 25 mg</title>
            <description>Treatment with Empa 25 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-tz</title>
          <description>area under the concentration-time curve of the analyte in plasma over the time interval from 0 to last quantifiable plasma concentration</description>
          <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216" spread="18.4"/>
                    <measurement group_id="O2" value="937" spread="44.2"/>
                    <measurement group_id="O3" value="2040" spread="19.5"/>
                    <measurement group_id="O4" value="5180" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-∞</title>
        <description>area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity</description>
        <time_frame>Predose and 15 minutes (min), 30min, 45min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 23h55min after first drug administration</time_frame>
        <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 1 mg</title>
            <description>Treatment with Empa 1 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Empa 5 mg</title>
            <description>Treatment with Empa 5 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Empa 10 mg</title>
            <description>Treatment with Empa 10 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Empa 25 mg</title>
            <description>Treatment with Empa 25 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞</title>
          <description>area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity</description>
          <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="249" spread="15.5"/>
                    <measurement group_id="O2" value="1070" spread="44.5"/>
                    <measurement group_id="O3" value="2320" spread="18.1"/>
                    <measurement group_id="O4" value="5930" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax</title>
        <description>maximum measured concentration of the analyte in plasma</description>
        <time_frame>Predose and 15 minutes (min), 30min, 45min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 23h55min after first drug administration</time_frame>
        <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 1 mg</title>
            <description>Treatment with Empa 1 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Empa 5 mg</title>
            <description>Treatment with Empa 5 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Empa 10 mg</title>
            <description>Treatment with Empa 10 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Empa 25 mg</title>
            <description>Treatment with Empa 25 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>maximum measured concentration of the analyte in plasma</description>
          <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5" spread="28.8"/>
                    <measurement group_id="O2" value="166" spread="47.6"/>
                    <measurement group_id="O3" value="358" spread="29.1"/>
                    <measurement group_id="O4" value="844" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t1/2</title>
        <description>terminal half-life of the analyte in plasma</description>
        <time_frame>Predose and 15 minutes (min), 30min, 45min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 23h55min after first drug administration</time_frame>
        <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 1 mg</title>
            <description>Treatment with Empa 1 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Empa 5 mg</title>
            <description>Treatment with Empa 5 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Empa 10 mg</title>
            <description>Treatment with Empa 10 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Empa 25 mg</title>
            <description>Treatment with Empa 25 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2</title>
          <description>terminal half-life of the analyte in plasma</description>
          <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
          <units>hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.55" spread="14.8"/>
                    <measurement group_id="O2" value="9.09" spread="15.0"/>
                    <measurement group_id="O3" value="9.14" spread="13.3"/>
                    <measurement group_id="O4" value="9.26" spread="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CL/F</title>
        <description>apparent clearance of the analyte in plasma after extravascular administration</description>
        <time_frame>Predose and 15 minutes (min), 30min, 45min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 23h55min after first drug administration</time_frame>
        <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 1 mg</title>
            <description>Treatment with Empa 1 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Empa 5 mg</title>
            <description>Treatment with Empa 5 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Empa 10 mg</title>
            <description>Treatment with Empa 10 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Empa 25 mg</title>
            <description>Treatment with Empa 25 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F</title>
          <description>apparent clearance of the analyte in plasma after extravascular administration</description>
          <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149" spread="15.5"/>
                    <measurement group_id="O2" value="173" spread="44.5"/>
                    <measurement group_id="O3" value="159" spread="18.1"/>
                    <measurement group_id="O4" value="156" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vz/F</title>
        <description>apparent volume of distribution during the terminal phase λz following an extravascular dose</description>
        <time_frame>Predose and 15 minutes (min), 30min, 45min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 23h55min after first drug administration</time_frame>
        <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 1 mg</title>
            <description>Treatment with Empa 1 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Empa 5 mg</title>
            <description>Treatment with Empa 5 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Empa 10 mg</title>
            <description>Treatment with Empa 10 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Empa 25 mg</title>
            <description>Treatment with Empa 25 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Vz/F</title>
          <description>apparent volume of distribution during the terminal phase λz following an extravascular dose</description>
          <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
          <units>Liter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123" spread="26.1"/>
                    <measurement group_id="O2" value="136" spread="46.3"/>
                    <measurement group_id="O3" value="126" spread="25.5"/>
                    <measurement group_id="O4" value="125" spread="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ae0-24</title>
        <description>amount of the analyte that is eliminated in urine over the time interval 0 to 24</description>
        <time_frame>0-5, 5-12, 12-24 hour after first drug administration</time_frame>
        <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 1 mg</title>
            <description>Treatment with Empa 1 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Empa 5 mg</title>
            <description>Treatment with Empa 5 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Empa 10 mg</title>
            <description>Treatment with Empa 10 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Empa 25 mg</title>
            <description>Treatment with Empa 25 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Ae0-24</title>
          <description>amount of the analyte that is eliminated in urine over the time interval 0 to 24</description>
          <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
          <units>nmol</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="338" spread="23.7"/>
                    <measurement group_id="O2" value="1640" spread="56.2"/>
                    <measurement group_id="O3" value="3460" spread="17.5"/>
                    <measurement group_id="O4" value="8550" spread="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>fe0-24</title>
        <description>fraction of the analyte excreted unchanged in urine from time interval 0 to 24</description>
        <time_frame>0-5, 5-12, 12-24 hour after first drug administration</time_frame>
        <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 1 mg</title>
            <description>Treatment with Empa 1 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Empa 5 mg</title>
            <description>Treatment with Empa 5 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Empa 10 mg</title>
            <description>Treatment with Empa 10 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Empa 25 mg</title>
            <description>Treatment with Empa 25 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>fe0-24</title>
          <description>fraction of the analyte excreted unchanged in urine from time interval 0 to 24</description>
          <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
          <units>percentage of Ae0-24 (to dosage)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" spread="23.7"/>
                    <measurement group_id="O2" value="14.8" spread="56.2"/>
                    <measurement group_id="O3" value="15.6" spread="17.5"/>
                    <measurement group_id="O4" value="15.4" spread="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CLR,0-24</title>
        <description>renal clearance of the analyte in plasma after extravascular administration – based on 0-24 hours data</description>
        <time_frame>Predose and 15 minutes (min), 30min, 45min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 23h55min, 0-5h, 5-12h, 12-24h after first drug administration</time_frame>
        <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 1 mg</title>
            <description>Treatment with Empa 1 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Empa 5 mg</title>
            <description>Treatment with Empa 5 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Empa 10 mg</title>
            <description>Treatment with Empa 10 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Empa 25 mg</title>
            <description>Treatment with Empa 25 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>CLR,0-24</title>
          <description>renal clearance of the analyte in plasma after extravascular administration – based on 0-24 hours data</description>
          <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.7" spread="21.2"/>
                    <measurement group_id="O2" value="28.7" spread="27.3"/>
                    <measurement group_id="O3" value="28.3" spread="24.4"/>
                    <measurement group_id="O4" value="27.5" spread="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUCτ,ss</title>
        <description>area under the concentration-time curve of the analyte in plasma over a uniform dosing interval τ at steady state</description>
        <time_frame>Predose and 15 minutes (min), 30min, 45min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h after last drug administration</time_frame>
        <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 1 mg</title>
            <description>Treatment with Empa 1 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Empa 5 mg</title>
            <description>Treatment with Empa 5 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Empa 10 mg</title>
            <description>Treatment with Empa 10 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Empa 25 mg</title>
            <description>Treatment with Empa 25 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>AUCτ,ss</title>
          <description>area under the concentration-time curve of the analyte in plasma over a uniform dosing interval τ at steady state</description>
          <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="277" spread="17.0"/>
                    <measurement group_id="O2" value="1270" spread="15.0"/>
                    <measurement group_id="O3" value="2580" spread="17.3"/>
                    <measurement group_id="O4" value="6330" spread="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax,ss</title>
        <description>maximum measured concentration of the analyte in plasma at steady state</description>
        <time_frame>Predose and 15 minutes (min), 30min, 45min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h 48h, 72h after last drug administration</time_frame>
        <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 1 mg</title>
            <description>Treatment with Empa 1 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Empa 5 mg</title>
            <description>Treatment with Empa 5 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Empa 10 mg</title>
            <description>Treatment with Empa 10 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Empa 25 mg</title>
            <description>Treatment with Empa 25 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax,ss</title>
          <description>maximum measured concentration of the analyte in plasma at steady state</description>
          <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.4" spread="32.3"/>
                    <measurement group_id="O2" value="182" spread="31.4"/>
                    <measurement group_id="O3" value="393" spread="28.0"/>
                    <measurement group_id="O4" value="836" spread="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t1/2,ss</title>
        <description>terminal half-life of the analyte in plasma at steady state</description>
        <time_frame>Predose and 15 minutes (min), 30min, 45min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h 48h, 72h after last drug administration</time_frame>
        <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 1 mg</title>
            <description>Treatment with Empa 1 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Empa 5 mg</title>
            <description>Treatment with Empa 5 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Empa 10 mg</title>
            <description>Treatment with Empa 10 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Empa 25 mg</title>
            <description>Treatment with Empa 25 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2,ss</title>
          <description>terminal half-life of the analyte in plasma at steady state</description>
          <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
          <units>hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" spread="45.5"/>
                    <measurement group_id="O2" value="11.9" spread="48.0"/>
                    <measurement group_id="O3" value="13.4" spread="37.7"/>
                    <measurement group_id="O4" value="16.4" spread="48.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CL/F,ss</title>
        <description>apparent clearance of the analyte in plasma after extravascular administration at steady state</description>
        <time_frame>Predose and 15 minutes (min), 30min, 45min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h 48h, 72h after last drug administration</time_frame>
        <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 1 mg</title>
            <description>Treatment with Empa 1 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Empa 5 mg</title>
            <description>Treatment with Empa 5 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Empa 10 mg</title>
            <description>Treatment with Empa 10 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Empa 25 mg</title>
            <description>Treatment with Empa 25 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>CL/F,ss</title>
          <description>apparent clearance of the analyte in plasma after extravascular administration at steady state</description>
          <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133" spread="17.0"/>
                    <measurement group_id="O2" value="146" spread="15.0"/>
                    <measurement group_id="O3" value="143" spread="17.3"/>
                    <measurement group_id="O4" value="146" spread="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vz/F,ss</title>
        <description>apparent volume of distribution during the terminal phase λz following an extravascular dose at steady state</description>
        <time_frame>Predose and 15 minutes (min), 30min, 45min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 36h 48h, 72h after last drug administration</time_frame>
        <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 1 mg</title>
            <description>Treatment with Empa 1 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Empa 5 mg</title>
            <description>Treatment with Empa 5 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Empa 10 mg</title>
            <description>Treatment with Empa 10 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Empa 25 mg</title>
            <description>Treatment with Empa 25 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Vz/F,ss</title>
          <description>apparent volume of distribution during the terminal phase λz following an extravascular dose at steady state</description>
          <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
          <units>Liter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141" spread="37.8"/>
                    <measurement group_id="O2" value="151" spread="48.6"/>
                    <measurement group_id="O3" value="166" spread="43.6"/>
                    <measurement group_id="O4" value="208" spread="51.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>RA,Cmax</title>
        <description>accumulation ratios of the analyte in plasma after 28 doses (once daily) over a uniform dosing interval τ, based on Cmax</description>
        <time_frame>Predose, 15min, 30min, 45min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 23h55min after first drug administration, and predose, 15min, 30min, 45min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h after last drug administration</time_frame>
        <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 1 mg</title>
            <description>Treatment with Empa 1 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Empa 5 mg</title>
            <description>Treatment with Empa 5 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Empa 10 mg</title>
            <description>Treatment with Empa 10 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Empa 25 mg</title>
            <description>Treatment with Empa 25 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>RA,Cmax</title>
          <description>accumulation ratios of the analyte in plasma after 28 doses (once daily) over a uniform dosing interval τ, based on Cmax</description>
          <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" spread="23.3"/>
                    <measurement group_id="O2" value="1.07" spread="54.2"/>
                    <measurement group_id="O3" value="1.16" spread="34.2"/>
                    <measurement group_id="O4" value="0.998" spread="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>RA,AUC</title>
        <description>accumulation ratios of the analyte in plasma after 28 doses (once daily) over a uniform dosing interval τ, based on AUCτ</description>
        <time_frame>Predose, 15min, 30min, 45min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 23h55min after first drug administration, and predose, 15min, 30min, 45min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h after last drug administration</time_frame>
        <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 1 mg</title>
            <description>Treatment with Empa 1 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Empa 5 mg</title>
            <description>Treatment with Empa 5 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Empa 10 mg</title>
            <description>Treatment with Empa 10 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Empa 25 mg</title>
            <description>Treatment with Empa 25 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>RA,AUC</title>
          <description>accumulation ratios of the analyte in plasma after 28 doses (once daily) over a uniform dosing interval τ, based on AUCτ</description>
          <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" spread="9.21"/>
                    <measurement group_id="O2" value="1.32" spread="42.5"/>
                    <measurement group_id="O3" value="1.32" spread="13.1"/>
                    <measurement group_id="O4" value="1.23" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ae0-24,ss</title>
        <description>amount of the analyte that is eliminated in urine at steady state over the time interval 0 to 24</description>
        <time_frame>0-5, 5-12, 12-24 hour after last drug administration</time_frame>
        <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 1 mg</title>
            <description>Treatment with Empa 1 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Empa 5 mg</title>
            <description>Treatment with Empa 5 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Empa 10 mg</title>
            <description>Treatment with Empa 10 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Empa 25 mg</title>
            <description>Treatment with Empa 25 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Ae0-24,ss</title>
          <description>amount of the analyte that is eliminated in urine at steady state over the time interval 0 to 24</description>
          <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
          <units>nmol</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="479" spread="27.2"/>
                    <measurement group_id="O2" value="2250" spread="44.5"/>
                    <measurement group_id="O3" value="4780" spread="18.6"/>
                    <measurement group_id="O4" value="11500" spread="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>fe0-24,ss</title>
        <description>fraction of the analyte excreted unchanged in urine at steady state from time interval 0 to 24</description>
        <time_frame>0-5, 5-12, 12-24 hour after last drug administration</time_frame>
        <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 1 mg</title>
            <description>Treatment with Empa 1 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Empa 5 mg</title>
            <description>Treatment with Empa 5 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Empa 10 mg</title>
            <description>Treatment with Empa 10 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Empa 25 mg</title>
            <description>Treatment with Empa 25 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>fe0-24,ss</title>
          <description>fraction of the analyte excreted unchanged in urine at steady state from time interval 0 to 24</description>
          <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
          <units>percentage of Ae0-24 (to dosage)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" spread="27.2"/>
                    <measurement group_id="O2" value="20.3" spread="44.5"/>
                    <measurement group_id="O3" value="21.6" spread="18.6"/>
                    <measurement group_id="O4" value="20.8" spread="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CLR,ss</title>
        <description>renal clearance of the analyte at steady state determined over the dosing interval τ</description>
        <time_frame>Predose and 15 minutes (min), 30min, 45min, 1 hour (h), 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 0-5h, 5-12h, 12-24h after last drug administration</time_frame>
        <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
        <group_list>
          <group group_id="O1">
            <title>Empa 1 mg</title>
            <description>Treatment with Empa 1 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Empa 5 mg</title>
            <description>Treatment with Empa 5 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Empa 10 mg</title>
            <description>Treatment with Empa 10 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Empa 25 mg</title>
            <description>Treatment with Empa 25 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>CLR,ss</title>
          <description>renal clearance of the analyte at steady state determined over the dosing interval τ</description>
          <population>Pharmacokinetic analysis set: all patients who received at least one dose of BI 10773 and had some pharmacokinetic data</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8" spread="25.2"/>
                    <measurement group_id="O2" value="29.6" spread="40.5"/>
                    <measurement group_id="O3" value="30.9" spread="28.1"/>
                    <measurement group_id="O4" value="30.3" spread="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Between the first drug administration and the end of the trial after the last drug administration, up to 28 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Treatment with placebo once daily</description>
        </group>
        <group group_id="E2">
          <title>Empa 1 mg</title>
          <description>Treatment with Empa 1 mg once daily</description>
        </group>
        <group group_id="E3">
          <title>Empa 5 mg</title>
          <description>Treatment with Empa 5 mg once daily</description>
        </group>
        <group group_id="E4">
          <title>Empa 10 mg</title>
          <description>Treatment with Empa 10 mg once daily</description>
        </group>
        <group group_id="E5">
          <title>Empa 25 mg</title>
          <description>Treatment with Empa 25 mg once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Heat illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alpha 1 microglobulin urine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Beta 2 microglobulin urine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Additional secondary endpoints were listed in the original protocol. Those endpoints are of exploratory nature only and were not considered relevant for trial conclusions. For more information see tab “Full Text Review”, section “More Information”.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

